Ovarian Neoplasms
📧 Sign up to get email alerts when something new happens for Ovarian Neoplasms.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-19EMA Authorised: Rubraca (rucaparib camsylate) — pharmaand GmbH
The EMA authorises Rubraca (rucaparib camsylate) for ovarian neoplasms, with pharmaand GmbH as the marketing authorisation holder.
-
EMA approval · 2026-08-12EMA Authorised: Lynparza (olaparib) — AstraZeneca AB
Olaparib (Lynparza) has been authorised by the EMA for multiple indications across ovarian, breast, pancreatic, and castration-resistant pro…
-
EMA approval · 2026-07-20EMA Authorised: Yondelis (trabectedin) — Pharma Mar S.A.
Authorised status for Yondelis (trabectedin) in the EU for ovarian neoplasms and sarcoma.
-
EMA approval · 2026-07-07EMA Authorised: Abevmy (bevacizumab) — Biosimilar Collaborations Ireland Limited
EMA authorises a biosimilar version of bevacizumab (Abevmy) for multiple cancer indications, expanding access to this biologic therapy.
-
EMA approval · 2026-06-10EMA Authorised: Zejula (niraparib (tosilate monohydrate)) — GlaxoSmithKline Trading Services Limited
The EMA authorised Zejula (niraparib tosilate monohydrate) for ovarian, fallopian tube, and peritoneal neoplasms, under GlaxoSmithKline Trad…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-06-03EMA Authorised: Lynparza (olaparib) — AstraZeneca AB
Olaparib (Lynparza) has been authorised by the EMA for multiple neoplasms including ovarian, breast, pancreatic, and castration-resistant pr…
-
EMA approval · 2025-11-27EMA Authorised: Rubraca (rucaparib camsylate) — pharmaand GmbH
The EMA has authorised Rubraca (rucaparib camsylate) in the EU for ovarian neoplasms. The marketing authorisation holder is pharmaand GmbH.
-
EMA approval · 2025-11-26EMA Authorised: Zejula (niraparib (tosilate monohydrate)) — GlaxoSmithKline Trading Services Limited
The EMA authorised Zejula for fallopian tube neoplasms, peritoneal neoplasms, and ovarian neoplasms. GlaxoSmithKline Trading Services Limite…
-
EMA approval · 2025-06-18EMA Authorised: Phelinun (melphalan hydrochloride) — ADIENNE S.r.l. S.U.
The EMA authorised Phelinun (melphalan hydrochloride) for multiple cancers including multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphom…
-
EMA approval · 2025-04-03EMA Authorised: Yondelis (trabectedin) — Pharma Mar S.A.
EU marketing authorisation granted for Yondelis (trabectedin) for ovarian neoplasms and soft tissue sarcoma.